According to the company, the new synthetic peptide vaccine, which targets beta-amyloid, achieved its primary endpoints in a double-blind, placebo-controlled study on safety and immunogenicity, with a 96% immune response rate. Participants in the clinical trial received the experimental vaccine over an extended period following two different dosing regimens.

Currently, there is no active vaccination available against beta-amyloid, making these trial results particularly significant, as no serious adverse effects have been reported.

Additional data, including results from secondary endpoint analyses, are expected to be presented at upcoming medical forums—specifically, the 14th International Conference on Alzheimer’s and Parkinson’s Diseases—and will also be published in peer-reviewed medical journals.

Participants from the completed clinical trial will be enrolled in a long-term extension study, where they will continue receiving the UB-311 vaccine. 

Source: United Neuroscience